

ADHD Guideline Committee Meeting 14

Date and Time: Thursday 16 November 2017, 10:00-16:00

Place: Boardroom, National Guideline Centre

Minutes: Draft

| | | |
|-----------------|--------------------------|---|
| Present: | Gillian Baird (GB) | Professor of Paediatric Neurodisability and Consultant Developmental Paediatrician, Chair |
| | Emily Simonoff (ES) | Professor of Child & Adolescent Psychiatry, Clinical Specialist |
| | Philip Asherson (PA) | Professor of Psychiatry and Honorary Consultant Psychiatrist |
| | Polly Branney (PB) | General Practitioner |
| | Poppy Ellis Logan (PEL) | Lay Member |
| | Jean Fitzpatrick (JF) | Lay Member |
| | Gisli Gudjonsson (GG) | Professor of Psychology |
| | Chris Hollis (CH) | Professor of Child & Adolescent Psychiatry and Consultant in Developmental Neuropsychiatry |
| | Nicole Horwitz (NH) | Consultant Community Paediatrician |
| | Jen Lewis-Neill (JLN) | Clinical Lead/Independent Nurse Prescriber |
| | Karen Pratt (KP) | Paediatric Nurse Specialist for Neurodisability |
| | Jonathan Rackham (JR) | Lay Member |
| | Kapil Sayal (KS) | Professor of Child & Adolescent Psychiatry and Honorary Consultant Psychiatrist |
| | David Traxson (DT) | Educational Psychologist |
| | Jody Warner-Rogers (JWR) | Consultant Clinical Psychologist and Paediatric Neuropsychologist |
| | Ian Wong (IW) | Professor of Pharmacy Practice and Medicine Evaluation |

NICE team

| | |
|---------------------------|----------------------------------|
| Anne-Louise Clayton (ALC) | Senior Medical Editor |
| Ben Doak (BD) | Guidelines Commissioning Manager |

NGC technical team

| | |
|-------------------------|-------------------------|
| Kate Ashmore (KA) | Project Manager |
| Margaret Constanti (MC) | Senior Health Economist |
| James Gilbert (JG) | Senior Research Fellow |
| Kate Kelley (KK) | Guideline Lead |

Apologies

| | |
|--------------------|--|
| Marios Adamou (MA) | Consultant Psychiatrist (adults) and Visiting Professor |
| Rebecca Boffa (RB) | Research Fellow, NGC |
| Rafina Yarde (RY) | Research Fellow, NGC |

Notes

1. The Chair welcomed the group to the fourteenth meeting of this GC. Apologies were received from MA, RB and RY.
2. The Chair reviewed and requested updates to the declarations of interest register.
3. The following new declarations were received for this meeting:

| GC Declarations of Interest | | | |
|--|--|---|--|
| N.B. The Chair and GC members were recruited to this guideline using NICE DOI policy published September 2014. | | | |
| Insert initials | Declaration | Classification (as per the NICE DOI policy wording*) | Chair's action |
| ES | I am a co-applicant on a programme grant application to NIHR that will be submitted later this year. The focus of the application is to evaluate the effectiveness and cost-effectiveness of a parenting intervention for children at risk of ADHD. The intervention would be an online platform and families would be randomized following a referral to CAMHS services. | Personal non-financial specific | Declare and participate |
| PA | <ol style="list-style-type: none"> 1. 6th July: teaching of health care professionals on diagnosis of ADHD for UK Adult ADHD Network (UKAAN). Speaker fee to King's College London. 2. 14th and 15th September. Shire sponsored meeting. Gave general educational talk to European psychiatrists on differential diagnosis of ADHD. A fee for this work was paid to King's College London. 3. ECNP conference – invited by conference organisation for plenary talk on emotional dysregulation in ADHD. No payment other than travel, accommodation and conference registration costs paid by ECNP. 4. 21st – 23rd September: Was the conference organiser for the UKAAN meeting on "ADHD in the mainstream". This meeting was supported in part with sponsorship from commercial companies involved in drug treatment or diagnostic systems for ADHD. | <ol style="list-style-type: none"> 1. Personal financial specific 2. Personal financial specific 3. Personal, non-financial specific 4. Personal financial specific 5. Personal financial specific 6. Personal non-financial specific 7. Personal non-financial specific 8. Personal non-financial specific | <ol style="list-style-type: none"> 1. Declare and participate 2. Declare and participate 3. Declare and participate 4. Declare and participate 5. Declare and participate 6. Declare and participate 7. Declare and participate 8. Declare and participate 9. Declare and participate |

| | | | |
|-----|---|--|--|
| | <ol style="list-style-type: none"> 29th September. Teaching of health care professionals on diagnosis of ADHD for UK Adult ADHD Network (UKAAN). Speaker fee to King's College London. Eunethydis 2-5 October. Chaired session on ADHD as a lifespan disorder. No payments. 13-15 October. World Congress of psychiatric genetics. Chaired session on genetic epidemiology of ADHD in population samples. No payments. 26th October: Dundee and Perth ADHD support group: talk on mind wandering and ADHD. No payment other than travel costs. ADHD Foundation: talk on mind wandering and ADHD. No payment other than travel costs. Brussels policy meeting December 6th to discuss research on treatment of ADHD on offenders, and the trial of Concerta that I am currently PI. This policy implementation meeting is funded by an EU program grant. | <ol style="list-style-type: none"> financial specific Person al non-financial specific Person al non-financial specific | <ol style="list-style-type: none"> 10. Declare and participate |
| PEL | <ol style="list-style-type: none"> 1. Attended the ADHD Foundation conference 2. Co-authored 'A Lifetime Lost' - report commissioned by Shire & ADHD Foundation among others (https://www.adhdfoundation.org.uk/wp-content/uploads/2017/11/A-Lifetime-Lost-or-a-Lifetime-Saved-report.pdf) 3. Began building ADHD website for Psychiatry-UK LLP 4. Invited to speak at UKAAN Conference on "Impact of ADHD in higher education and reasonable adjustments" (Sept 2017) | <ol style="list-style-type: none"> 1. Person al non-financial specific 2. Person al non-financial specific 3. Person al non-financial specific 4. Person al non-financial specific | <ol style="list-style-type: none"> 1. Declare and participate 2. Declare and participate 3. Declare and participate 4. Declare and participate |
| NH | <ol style="list-style-type: none"> 1. Lecture on 'Is Autism a social construct?' given on 18.7.17. Complex ASD study day, Great Ormond Street Hospital. 14/11/2017 2. Lecture on 'Is Autism a social construct?' given on 15.9.17. | <ol style="list-style-type: none"> 1. Person al financial non-specific 2. Person al non-financial | <ol style="list-style-type: none"> 1. Declare and participate 2. Declare and participate |

| | | | |
|-----|--|---|---|
| | <p>ACAMH LD special Interest Group</p> <p>3. Lecture on 'Is Autism a social construct?' given on 28.9.17. Community of Health meeting, Cardiff.</p> <p>4. I organised and chaired the 'Community Child Health' meeting on 2-3.10.17. 14/11/2017</p> <p>5. Market research 30 minute telephone interview about managing ADHD, July 2018, for undisclosed client. Management in general discussed. No specific interventions/ medications discussed.</p> | <p>non-specific</p> <p>3. Personal non-financial non-specific</p> <p>4. Personal, non-financial non-specific</p> <p>5. Personal, financial specific</p> | <p>3. Declare and participate</p> <p>4. Declare and participate</p> <p>5. Declare and participate</p> |
| JLN | UKAAN September 22 nd 2017: 'Ask the Experts' Panel promoted by SHIRE on use of Amfetamines in ADHD. This consisted of discussion with the audience about prescribing amphetamines for adults with ADHD. | Personal, non-financial, non-specific | Declare and participate |
| KS | Lead author on a research paper on "Relative age within the school year and diagnosis of attention-deficit hyperactivity disorder: a nationwide population-based study." Published in the Lancet Psychiatry. | Non-personal financial specific | Declare and participate |
| DT | I led a workshop at the National Congress of French School Psychologists in Montpellier on Friday 22 nd September – it was entitled, 'Using the HPP Model of Mental Health and Wellbeing to Assess the Mental Health Needs of Young People.' 23/11/2017 | Personal financial non-specific | Declare and participate |
| IW | <p>1. Keynote Speech - Beyond symptom control in ADHD: the contribution of pharmacoepidemiology in addressing benefit and risk. 10th Asian Conference on Pharmacoepidemiology (ACPE) 29 – 31 Oct 2017. Brisbane Australia. (Conference organiser</p> | <p>1. Personal non-financial specific</p> <p>2. Personal non-financial specific</p> <p>3. Personal non-</p> | <p>1. Declare and participate</p> <p>2. Declare and participate</p> <p>3. Declare and participate</p> |

| | | | |
|--|--|---|---|
| | <p>provided transport and accommodation).</p> <p>2. Keynote Speech - Treatment effects on criminality, violence, drug abuse, accidents and other high risk outcomes. ADHD in the Mainstream Impact, Impairment and Innovation UK Adult ADHD Network (UKAAN) meeting. September 21 - 23 2017. London UK. (No honorarium or reimbursement of expenses).</p> <p>3. Seminar on Application of pharmacoepidemiology in ADHD research. University of Sydney on 3rd Nov 2017. (UoS provided 1 night accommodation).</p> <p>4. Appointment of the independent non-executive director of Jacobson Pharma in Hong Kong from 1st Dec 2017. The company has no pharmaceutical products licensed in the UK. (I will receive salary).</p> <p>5. Speaking at 11th Janssen Pharmacy Academy for Senior Mental Health Pharmacists on "ADHD - treatment options" on 21st Nov 2017. (I will receive honorarium from Janssen).</p> | <p>financial specific</p> <p>4. Personal financial non-specific</p> <p>5. Personal financial specific</p> | <p>4. Declare and participate</p> <p>5. Declare and participate</p> |
| <p>NICE DOI policy classifications are:</p> <ul style="list-style-type: none"> • Personal financial specific • Personal financial non-specific • Personal non-financial specific • Personal non-financial non-specific • Non-personal financial specific • Non-personal financial non-specific | | | |

4. The meeting notes and NICE minutes of the last meeting were reviewed by the committee. No amendments were required. The notes and NICE minutes were then agreed as a true and accurate record of the meeting.
5. The committee reviewed the stakeholder consultation comments and made edits to the recommendations.
6. JG reviewed the wording of the recommendations with the committee in order to sign off any changes made in response to the stakeholder comments.
7. AOB: next steps were discussed.